CN109574867A - 一种钌催化芳基胺化合物的不对称氢化合成手性三级胺的方法 - Google Patents

一种钌催化芳基胺化合物的不对称氢化合成手性三级胺的方法 Download PDF

Info

Publication number
CN109574867A
CN109574867A CN201710906866.2A CN201710906866A CN109574867A CN 109574867 A CN109574867 A CN 109574867A CN 201710906866 A CN201710906866 A CN 201710906866A CN 109574867 A CN109574867 A CN 109574867A
Authority
CN
China
Prior art keywords
ruthenium
catalyst
ligand
substrate
tertiary amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201710906866.2A
Other languages
English (en)
Other versions
CN109574867B (zh
Inventor
严忠
谢焕平
孙蕾
周永贵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dalian Institute of Chemical Physics of CAS
Original Assignee
Dalian Institute of Chemical Physics of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dalian Institute of Chemical Physics of CAS filed Critical Dalian Institute of Chemical Physics of CAS
Priority to CN201710906866.2A priority Critical patent/CN109574867B/zh
Publication of CN109574867A publication Critical patent/CN109574867A/zh
Application granted granted Critical
Publication of CN109574867B publication Critical patent/CN109574867B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2409—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
    • B01J31/2414—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom comprising aliphatic or saturated rings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2419—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising P as ring member
    • B01J31/2428—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising P as ring member with more than one complexing phosphine-P atom
    • B01J31/2433—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising P as ring member with more than one complexing phosphine-P atom comprising aliphatic or saturated rings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2442—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems
    • B01J31/2447—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as substituents on a ring of the condensed system or on a further attached ring
    • B01J31/2452—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as substituents on a ring of the condensed system or on a further attached ring with more than one complexing phosphine-P atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F17/00—Metallocenes
    • C07F17/02—Metallocenes of metals of Groups 8, 9 or 10 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C07F9/650994—Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
    • C07F9/65683—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/60—Reduction reactions, e.g. hydrogenation
    • B01J2231/64—Reductions in general of organic substrates, e.g. hydride reductions or hydrogenations
    • B01J2231/641—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes
    • B01J2231/646—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes of aromatic or heteroaromatic rings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/02—Compositional aspects of complexes used, e.g. polynuclearity
    • B01J2531/0202—Polynuclearity
    • B01J2531/0205—Bi- or polynuclear complexes, i.e. comprising two or more metal coordination centres, without metal-metal bonds, e.g. Cp(Lx)Zr-imidazole-Zr(Lx)Cp
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/821—Ruthenium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

一种钌‑双膦配体催化9‑酰胺菲化合物的不对称氢化合成手性三级胺的方法。采用2‑5mol％钌催化剂，加入4‑10mol％氟硼酸，对9‑酰胺菲化合物进行不对称氢化，得到相应的手性三级胺化合物，其对映体过量可达到98％。本发明操作简便实用易行，收率高，环境友好，催化剂商业可得，反应条件温和，具有潜在的实际应用价值。

Description

一种钌催化芳基胺化合物的不对称氢化合成手性三级胺的 方法
技术领域
本发明涉及一种应用钌的均相体系高度对映选择性催化芳基胺化合物不对称氢化合成手性三级胺的方法。
背景技术
近年来，芳香杂环化合物的不对称氢化已经取得了很大的进展。多样的芳香杂环化合物，诸如：吲哚、吡啶、吡咯、喹啉等均能通过不对称催化实现高立体选择性的氢化反应得到相应的杂环化合物(参考文献一：(a)Wang,D.S.；Chen,Q.A.；Li,W.；Yu,C.-B.；Zhou,Y.-G.；Zhang,X.J.Am.Chem.Soc.2010,132,8909.(b)Ye,Z-S.；Chen,M.-W.；Chen,Q.-A.；Shi,L.；Duan,Y.；Zhou,Y.-G.Angew.Chem.Int.Ed.2012,51,10181.(c)Wang,D.-S,；Ye,Z.-S.；Chen,Q.-A.；Zhou,Y.-G.J.Am.Chem.Soc.2011,133,8866.(d)Wang,W.-B.；Lu,S-M.；Yang,P.-Y.；Han,X.-W.；Zhou,Y.-G.J.Am.Chem.Soc.2003,125,10536.)。但是相比于不含杂原子的芳香化合物而言，归因于其稳定的芳香性和缺少配位位点，其不对称氢化一直是一个充满挑战的课题。
2011年，Glorius小组发展了一种钌/N-杂环卡宾配合物催化喹喔啉底物的区域选择性氢化，最高能以88％ee实现5,6,7,8-四氢喹喔啉的合成(参考文献二：Urban,S.；Ortega,N.；Glorius,F.Angew.Chem.Int.Ed.2011,50,3803.)；
随后，Kuwano小组使用其发展的PhTrap配体成功实现了萘环和喹啉中全碳芳环的不对称氢化，能取得较好的结果，但是苛刻的温度条件是需要的(参考文献三：(a)Kuwano,R.；Morioka,R.；Kashiwabara,M.；Kameyama,N.Angew.Chem.Int.Ed.2012,51,4136.(b)Kuwano,R.；Ikeda,R.；Hirasada,K.Chem.Commun.2015,51,7558.)。
然而，相比于芳香杂环化合物，不含杂原子的芳香化合物及其官能化衍生物的不对称氢化始终是一个充满挑战的方向。
发明内容
本发明的目的是提供一种钌催化芳基胺化合物，尤其是9-酰胺菲化合物的不对称氢化合成手性三级胺的方法。为实现上述目的，本发明采用的技术方案如下：
本发明以钌的手性双膦P-P*配合物催化剂，实现芳基胺的不对称氢化，反应式和条件如下：
式中：
R为C1-C4的烷基或芳基；R’为甲基、乙基和甲氧基中的一种或两种以上；R1为甲基、甲氧基中的一种或两种以上；R2为甲基、甲氧基和F中的一种或两种以上。
所述氢化反应包括催化剂制备和底物氢化两个阶段：
(1)催化剂制备，将钌金属前体和手性双膦配体，氟硼酸加入有机溶剂后反应得到，反应条件如下：把钌的金属前体、手性双膦配体和氟硼酸加入到有机溶剂中，在室温搅拌下0.5小时，然后直接用于氢化反应。
(2)氢化反应，将上述催化剂和有机溶剂加入9-酰胺菲底物中，通入氢气反应得到产物，反应条件如下：氮气保护下，上述催化剂和有机溶剂加入9-酰胺菲底物中，移至反应釜中，通入氢气，一定温度下下反应24小时；释放氢气，除去溶剂后直接柱层析分离得到纯的产物。
所述催化剂制备中，钌的金属前体及双膦配体均为市售且无需任何处理。
所述催化剂制备和氢化反应中，有机溶剂均选自二氯甲烷、1,2-二氯乙烷、甲醇、异丙醇和四氢呋喃中的一种，其中二氯甲烷和四氢呋喃稍差，乙酸乙酯和异丙醇较好，甲醇、乙醇和1,2-二氯乙烷较优。
所述钌金属前体选自双-(2-甲基烯丙基)环辛-1,5-二烯钌。
所述配体选自(1R,1’R,2S,2’S)-DuanPhos,(S,S)-MeDuPhos,(S,S)-iPrDuPhos,(S,S)-MeFerrocelane,(R,R)-iPrFerrocelane,(R)-(S)-Cy2PF-PtBu2,(R,R)-QuinoxP，优选双膦配体：(S,S)-iPrDuPhos和(R)-(S)-Cy2PF-PtBu2。
所述催化剂制备中：钌的金属前体、手性双膦配体、氟硼酸、底物摩尔比为：0.02-0.05：0.022-0.055：0.04-0.10：1。
所述不对称氢化反应时，反应压力为10-1000psi,优选600psi-1000psi，反应温度为0-80℃，优选30-60℃。
所述底物制备中，酰胺基团的引入对对映选择性的控制是必要的，其它取代基团如羟基、烷氧基、甲酸酯基不适用。
本发明有益效果：
1.反应活性和对映选择性高，反应完全，生成产物专一，核磁氢谱没有检测到副反应，使得能分离方便，能获得高的对映体过量纯品；
2.催化剂制备方便，反应操作简便实用；
3.氢化反应条件温和。
具体实施方式
下面通过实施例详述本发明，但本发明并不限于下述的实施例。
实施例1：单取代底物氢化反应条件的优化
在反应瓶中投入双-(2-甲基烯丙基)环辛-1,5-二烯钌(底物用量的2mol％-5mol％)和手性双膦配体(底物用量的2.2mol％-5.5mol％)，氮气置换后加入有机溶剂(1.0-2.0mL)和氟硼酸(底物用量的4mol％-10mol％)，室温搅拌0.5小时；然后用有机溶剂(1.0-2.0mL)将此溶液转到预先放有芳基胺底物1a(0.1mmol)的反应瓶中，移至反应釜中，通入氢气(600psi-1000psi)，0-50℃下反应24小时；释放氢气，除去溶剂后直接柱层析分离得到纯的产物，反应式和配体结构如下：
其产率为转化率，产物的对映体过量用手性液相色谱测定，详见表1。
表1.N-乙酰基-9-菲胺1a的不对称氢化条件优化a
实施例2：钌催化不对称氢化合成手性三级胺2
在反应瓶中投入双-(2-甲基烯丙基)环辛-1,5-二烯钌(底物用量的5mol％)和(S,S)-iPrDuPhos(底物用量的5.5mol％)，氮气置换后加入有机溶剂(1.0mL)和氟硼酸(底物用量的10mol％)，室温搅拌0.5小时；然后用有机溶剂(1.0mL)将此溶液转到预先放有芳基胺底物1(0.2mmol)的反应瓶中，移至反应釜中，通入氢气(1000psi)，30℃下反应24小时；释放氢气，除去溶剂后直接柱层析分离得到纯的产物，反应式如下：
产率为分离收率，产物的对映体过量用手性液相色谱测定，见表2。
表2.钌催化不对称氢化合成手性三级胺2a
实施例3：二取代底物氢化反应条件的优化
在反应瓶中投入双-(2-甲基烯丙基)环辛-1,5-二烯钌(底物用量的5mol％)和手性双膦配体(底物用量的5.5mol％)，氮气置换后加入有机溶剂(1.0mL)和氟硼酸(底物用量的10mol％)，室温搅拌0.5小时；然后用有机溶剂(1.0mL)将此溶液转到预先放有芳基胺底物3e(0.1mmol)的反应瓶中，移至反应釜中，通入氢气(1000psi)，30℃下反应24小时；释放氢气，除去溶剂后直接柱层析分离得到纯的产物，反应式如下：
产率为转化率，产物的对映体过量用手性液相色谱测定，见表3。
表3.N-乙酰基-10-甲基-9-菲胺3e的不对称氢化条件优化a
实施例4：钌催化不对称氢化合成手性三级胺4
在反应瓶中投入双-(2-甲基烯丙基)环辛-1,5-二烯钌(底物用量的5mol％)和L8(底物用量的5.5mol％)，氮气置换后加入异丙醇(2.0mL)和氟硼酸(底物用量的10mol％)，室温搅拌0.5小时；然后用异丙醇(2.0mL)将此溶液转到预先放有芳基胺底物3(0.2mmol)的反应瓶中，移至反应釜中，通入氢气(1000psi)，30℃下反应24小时；释放氢气，除去溶剂后直接柱层析分离得到纯的产物，反应式如下：
产率为分离收率，产物的对映体过量用手性液相色谱测定，见表4。
表4.钌催化不对称氢化合成手性三级胺4a
(S)-N-(9,10-Dihydrophenanthren-9-yl)acetamide(2a):45mg,95％yield,93％ee,[α]20 D＝-164.87(c 0.84,CHCl3),unknown compound,white solid,m.p.＝179-180℃,Rf＝0.50(diethyl ether).1H NMR(400MHz,＝0.7 mL/min,retention time 18.0 min and 22.2 min(maj).HRMS Calculated forC16H16NO[M+H]+238.1226,found 238.1229.
(S)-N-(9,10-Dihydrophenanthren-9-yl)propionamide(2b):48 mg,95％yield,90％ee,[α]20 D＝-150.10133.8,133.6,133.6,129.8,128.9,128.4,128.4,128.2,127.8,124.3,124.0,47.2,35.2,29.9,9.9.HPLC:Chiralcel AS-H column,254 nm,30 ℃,n-hexane/i-propanol＝70/30,flow＝0.7 mL/min,retention time 10.7 min and 13.6 min(maj).HRMS Calculatedfor C17H18NO[M+H]+252.1383,found 252.1381.
(S)-N-(9,10-Dihydrophenanthren-9-yl)pentanamide(2c):50mg,89％yield,88％ee,[α]20 D＝-116.87(c0.80,CHCl3),unknowncompound,white solid,m.p.＝105-106℃,Rf＝0.40(petroleum ether/diethyl124.0,47.3,36.8,35.2,27.9,22.5,13.9.HPLC:Chiralcel AS-H column,254 nm,30 ℃,n-hexane/i-propanol＝70/30,flow＝0.7 mL/min,retention time 11.1 min and 16.6min(maj).HRMS Calculated for C19H22NO[M+H]+280.1696,found 280.1696.
(S)-N-(9,10-Dihydrophenanthren-9-yl)pivalamide(2d):23 mg,41％yield,75％ee,[α]20 D＝-59.11(c0.34,CHCl3),unknown compound,colorless oil,Rf＝0.50(petroleum ether/dichloromethane 1/1).1H NMR(400n-hexane/i-propanol＝70/30,flow＝0.7 mL/min,retention time 5.6 min and 6.1min(maj).HRMS Calculated for C19H22NO[M+H]+280.1696,found 280.1697.
(S)-N-(9,10-Dihydrophenanthren-9-yl)benzamide(2e):58 mg,97％yield,79％ee,[α]20 D＝-92.55(c0.94,CHCl3),unknown compound,white solid,m.p.＝194-195℃,Rf＝0.50(petroleum ether/dichloromethane35.3.HPLC:Chiralcel AS-H column,254 nm,30 ℃,n-hexane/i-propanol＝70/30,flow＝0.7 mL/min,retention time 13.5 min and 16.9 min(maj).HRMS Calculated forC21H18NO[M+H]+300.1383,found 300.1384.
(S)-N-(9,10-Dihydrophenanthren-9-yl)-4-methylbenzamide(2f):53 mg,85％yield,82％ee,[α]20 D＝-95.81(c0.86,CHCl3),unknown compound,white solid,m.p.＝212-213℃,Rf＝0.50(petroleumether/dichloromethane 1/1).1H NMR(400 MHz,CDCl3)δ7.83(t,J＝6.8 Hz,2H),7.57-7.47(m,3H),
n-hexane/i-propanol＝70/30,flow＝0.7 mL/min,retention time 19.7 min and 25.5min(maj).HRMS Calculated for C22H20NO[M+H]+314.1539,found 314.1535.
(S)-N-(7-Methyl-9,10-dihydrophenanthren-9-yl)acetamide(2g):48 mg,95％yield,94％ee,[α]20 D＝-143.85(c 0.88,CHCl3),unknown compound,white solid,m.p.＝201-202℃,Rf＝0.20(petroleum124.2,123.7,47.4,35.2,23.7,21.4.HPLC:Chiralcel AS-H column,254 nm,30 ℃,n-hexane/i-propanol＝70/30,flow＝0.7 mL/min,retention time 14.8 min and 19.5min(maj).HRMS Calculated for C17H18NO[M+H]+252.1383,found 252.1383.
(S)-N-(7-Methoxy-9,10-dihydrophenanthren-9-yl)acetamide(2h):52 mg,97％yield,97％ee,[α]20 D＝-144.89(c 0.98,CHCl3),unknown compound,white solid,m.p.＝179-180℃,Rf＝0.20(petroleum
35.3,23.7.HPLC:Chiralcel AS-H column,254 nm,30 ℃,n-hexane/i-propanol＝70/30,flow＝0.7 mL/min,retention time 19.7 min and 35.1 min(maj).HRMS Calculatedfor C17H18NO2[M+H]+268.1332,found 268.1336.
(S)-N-(7-Fluoro-9,10-dihydrophenanthren-9-yl)acetamide(2i):46 mg,90％yield,94％ee,[α]20 D＝-145.10(c 0.92,CHCl3),unknown compound,white solid,m.p.＝225-226 ℃,Rf＝0.30(petroleum ether/diethyl
(d,J＝8.1 Hz),123.8,115.7(d,J＝21.5 Hz),114.9(d,J＝22.0 Hz),47.3,35.1,23.6；19FNMR(376 MHz,CDCl3)δ-113.4.HPLC:Chiralcel AS-H column,254 nm,30 ℃,n-hexane/i-propanol＝70/30,flow＝0.7mL/min,retention time 14.5 min and 18.0 min(maj).HRMS Calculated for C16H15FNO[M+H]+256.1132,found 256.1130.
(S)-N-(1-Methyl-9,10-dihydrophenanthren-9-yl)acetamide(2j):48 mg,95％yield,85％ee,[α]20 D＝-134.68(c 0.96,CHCl3),unknown compound,white solid,m.p.＝192-193 ℃,Rf＝0.20(petroleum ether/diethyl132.0,130.2,128.9,128.2,128.0,127.1,124.6,121.9,47.2,31.2,23.7,20.1.HPLC:Chiralcel AS-H column,254 nm,30 ℃,n-hexane/i-propanol＝70/30,flow＝0.7 mL/min,retention time 9.4 min and 14.5 min(maj).HRMS Calculated for C17H18NO[M+H]+252.1383,found252.138.
(S)-N-(2-Methyl-9,10-dihydrophenanthren-9-yl)acetamide(2k):45 mg,89％yield,1H),3.15-2.95(m,2H),2.37(s,3H),1.87(s,3H)；13C NMR(100 MHz,CDCl3)δ169.5,138.2,135.7,133.8,133.4,130.8,130.6,128.9,128.5,128.5,127.9,123.9,123.9,47.4,35.1,23.7,21.4.HPLC:Chiralcel AS-Hcolumn,254 nm,30 ℃,n-hexane/i-propanol＝70/30,flow＝0.7 mL/min,retention time 13.9 min and 21.5min(maj).HRMS Calculated forC17H18NO[M+H]+252.1383,found 252.1383.
(S)-N-(3-Methyl-9,10-dihydrophenanthren-9-yl)acetamide(2l):47 mg,93％yield,93％ee,[α]20 D＝-154.56(c 0.94,CHCl3),unknown compound,white solid,m.p.＝165-166 ℃,Rf＝0.20
128.9,128.8,128.4,128.2,124.6,124.1,47.5,34.7,23.6,21.6.HPLC:Chiralcel AS-Hcolumn,254 nm,30 ℃,n-hexane/i-propanol＝70/30,flow＝0.7 mL/min,retentiontime 18.2 min and 22.2 min(maj).HRMS Calculated for C17H18NO[M+H]+252.1383,found 252.1386.
N-((9S,10R)-10-Methoxy-9,10-dihydrophenanthren-9-yl)acetamide(4a):53 mg,99％yield,93％ee,d.r.>20:1,[α]20 D＝-91.03(c1.06,CHCl3),unknown compound,white solid,m.p.＝171-172℃,Rf＝0.50(diethyl50.7,23.7.HPLC:Chiralcel IC-H column,254 nm,30 ℃,n-hexane/i-propanol＝70/30,flow＝0.7 mL/min,retention time 11.8 min(maj)and 27.1 min.HRMS Calculated forC17H18NO2[M+H]+268.1332,found 268.1331.
N-((9S,10R)-10-Methoxy-7-methyl-9,10-dihydrophenanthren-9-yl)acetamide(4b):52 mg,92％yield,93％ee,d.r.>20:1,[α]20 D＝-64.03(c1.04,CHCl3),unknown compound,white solid,m.p.＝147-148 ℃,Rf＝0.5030 ℃,n-hexane/i-propanol＝70/30,flow＝0.7 mL/min,retention time 10.5 min(maj)and 26.7 min.HRMS Calculated for C18H20NO2[M+H]+282.1489,found 282.1490.
N-((9S,10R)-7,10-Dimethoxy-9,10-dihydrophenanthren-9-yl)acetamide(4c):59 mg,99％yield,94％ee,133.6,131.4,129.8,129.5,126.6,125.8,125.4,123.8,113.1,112.5,79.5,56.5,55.5,50.8,23.6.HPLC:Chiralcel IC-H column,254 nm,30 ℃,n-hexane/i-propanol＝70/30,flow＝0.7 mL/min,retention time 17.9 min(maj)and 30.8 min.HRMS Calculated forC18H20NO3[M+H]+298.1438,found 298.1436.
N-((9S,10R)-7-Fluoro-10-methoxy-9,10-dihydrophenanthren-9-yl)acetamide(4d):55 mg,96％yield,92％ee,d.r.>20:1,[α]20 D＝-109.27(c1.10,CHCl3),unknown compound,white solid,m.p.＝196-197 ℃,Rf＝131.6,130.1,129.9,129.2,127.4,125.9(d,J＝8.2 Hz),124.4,114.9(d,J＝21.6 Hz),113.6(d,J＝23.3 Hz),79.3,56.4,51.0,23.6；19F NMR(376 MHz,CDCl3)δ-113.1.HPLC:Chiralcel IC-H column,254 nm,30 ℃,n-hexane/i-propanol＝70/30,flow＝0.7 mL/min,retention time 10.5 min(maj)and 13.1 min.HRMS Calculated for C17H17FNO2[M+H]+286.1238,found 286.1239.
N-((9R,10R)-10-Methyl-9,10-dihydrophenanthren-9-yl)acetamide(4e):48mg,95％yield,83％ee,d.r.>20:1,[α]20 D＝+122.93(c 0.92,CHCl3),unknown compound,white solid,m.p.＝180-181 ℃,Rf＝0.60
254 nm,30 ℃,n-hexane/i-propanol＝70/30,flow＝0.7 mL/min,retention time 10.0min(maj)and 21.7min.HRMS Calculated for C17H18NO[M+H]+252.1383,found 252.1382.
N-((9R,10R)-10-Ethyl-9,10-dihydrophenanthren-9-yl)acetamide(4f):50 mg,94％yield,82％ee,d.r.>20:1,[α]20 D＝+43.00(c1.00,CHCl3),unknown compound,white solid,m.p.＝180-181 ℃,Rf＝0.50(diethyl20.7,12.1.HPLC:Chiralcel AS-H column,254 nm,30 ℃,n-hexane/i-propanol＝70/30,flow＝0.7 mL/min,retention time 9.7 min(maj)and 23.7 min.HRMS Calculated forC18H20NO[M+H]+266.1539,found 266.1539.

Claims (9)

1.一种钌催化9-酰胺菲化合物的不对称氢化合成手性三级胺的方法，催化体系为钌的手性双膦P-P*配合物，其特征在于：
式中：
R为C1-C4的烷基或芳基；R’为甲基、乙基和甲氧基中的一种或两种以上；R1为甲基、甲氧基中的一种或两种以上；R2为甲基、甲氧基和F中的一种或两种以上。
2.如权利要求1所述的方法，其特征在于：氢化反应包括催化剂制备和底物氢化两个阶段：(1)催化剂制备，将钌金属前体和手性双膦配体，氟硼酸加入有机溶剂后反应得到；(2)氢化反应，将催化剂和有机溶剂加入9-酰胺菲底物中，通入氢气反应得到产物。
3.如权利要求1或2所述的方法，其特征在于：所述催化剂为钌的金属前体和双膦配体的配合物，钌的金属前体及双膦配体均为市售且无需任何处理。
4.如权利要求2所述的合成方法，其特征在于：反应所用的有机溶剂选自二氯甲烷、1,2-二氯乙烷、甲醇、乙醇、异丙醇、乙酸乙酯和四氢呋喃中的一种，其中二氯甲烷或四氢呋喃稍差，乙酸乙酯或异丙醇较好，甲醇、乙醇或1,2-二氯乙烷较优。
5.如权利要求1或2所述的方法，其特征在于：所述钌金属前体选自双-(2-甲基烯丙基)环辛-1,5-二烯钌。
6.如权利要求1或2所述的方法，其特征在于：所述双膦配体选自所述配体选自(1R,1’R,2S,2’S)-DuanPhos,(S,S)-MeDuPhos,(S,S)-iPrDuPhos,(S,S)-MeFerrocelane,(R,R)-iPrFerrocelane,(R)-(S)-Cy2PF-PtBu2,或(R,R)-QuinoxP，优选双膦配体：(S,S)-iPrDuPhos或(R)-(S)-Cy2PF-PtBu2。
7.如权利要求1或2所述的方法，其特征在于：催化剂的制备过程物料配比为：钌的金属前体、手性双膦配体、氟硼酸、底物摩尔比为：0.02-0.05：0.022-0.055：0.04-0.10：1。
8.如权利要求1或2所述的方法，其特征在于：反应压力为10-1000psi,优选600psi-1000psi，反应温度为0-80℃，优选30-60℃。
9.如权利要求1或2所述的方法，其特征在于：底物摩尔浓度0.025-0.1。
CN201710906866.2A 2017-09-29 2017-09-29 一种钌催化芳基胺化合物的不对称氢化合成手性三级胺的方法 Active CN109574867B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710906866.2A CN109574867B (zh) 2017-09-29 2017-09-29 一种钌催化芳基胺化合物的不对称氢化合成手性三级胺的方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710906866.2A CN109574867B (zh) 2017-09-29 2017-09-29 一种钌催化芳基胺化合物的不对称氢化合成手性三级胺的方法

Publications (2)

Publication Number Publication Date
CN109574867A true CN109574867A (zh) 2019-04-05
CN109574867B CN109574867B (zh) 2021-06-15

Family

ID=65914564

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710906866.2A Active CN109574867B (zh) 2017-09-29 2017-09-29 一种钌催化芳基胺化合物的不对称氢化合成手性三级胺的方法

Country Status (1)

Country Link
CN (1) CN109574867B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111825508A (zh) * 2019-04-15 2020-10-27 中国科学院化学研究所 一种二氢化9-菲胺类化合物的制备方法及其制得的手性产品

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105859622A (zh) * 2015-01-22 2016-08-17 中国科学院大连化学物理研究所 钯催化不对称氢化合成手性氟代吡唑啉酮类衍生物的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105859622A (zh) * 2015-01-22 2016-08-17 中国科学院大连化学物理研究所 钯催化不对称氢化合成手性氟代吡唑啉酮类衍生物的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RYOICHI KUWANO等: "Catalytic Asymmetric Hydrogenation of Naphthalenes", 《ANGEW. CHEM.》 *
RYOICHI KUWANO等: "Catalytic asymmetric hydrogenation of quinoline carbocycles: unusual chemoselectivity in the hydrogenation of quinolines", 《CHEMCOMM》 *
SLAWOMIR URBAN等: "Ligand-Controlled Highly Regioselective and Asymmetric Hydrogenation of Quinoxalines Catalyzed by Ruthenium N-Heterocyclic Carbene Complexes", 《ANGEW. CHEM. INT. ED.》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111825508A (zh) * 2019-04-15 2020-10-27 中国科学院化学研究所 一种二氢化9-菲胺类化合物的制备方法及其制得的手性产品
CN111825508B (zh) * 2019-04-15 2021-11-16 中国科学院化学研究所 一种二氢化9-菲胺类化合物的制备方法及其制得的手性产品

Also Published As

Publication number Publication date
CN109574867B (zh) 2021-06-15

Similar Documents

Publication Publication Date Title
Oldenhuis et al. Catalytic acceptorless dehydrogenations: Ru-Macho catalyzed construction of amides and imines
Liu et al. Catalytic asymmetric addition of arylboronic acids to N-Boc imines generated in situ using C2-symmetric cationic N-heterocyclic carbenes (NHCs) Pd2+ diaquo complexes
Hong et al. Synthesis of planar chiral imidazo [1, 5-a] pyridinium salts based on [2.2] paracyclophane for asymmetric β-borylation of enones
CN109970795B (zh) 吡啶环上4-位取代手性螺环胺基膦配体制备方法及其应用
CN101845016A (zh) 一种铱催化不对称硅氢化合成手性四氢喹啉衍生物的方法
Li et al. Asymmetric Hydrogenation of Bis (quinolin‐2‐yl) methanes: A Direct Access to Chiral 1, 3‐Diamines
US20140336402A1 (en) Ligand forming asymmetrical transformation catalyst for making new pharmaceuticals
Vielhaber et al. Manganese-catalyzed homogeneous hydrogenation of ketones and conjugate reduction of α, β-unsaturated carboxylic acid derivatives: A chemoselective, robust, and phosphine-free in situ-protocol
Bao et al. Enantioselective Ring Opening of meso‐Epoxides with Aromatic Amines Catalyzed by Dinuclear Magnesium Complexes
CN111620793A (zh) 一种手性腈类化合物的制备方法
CN109574867A (zh) 一种钌催化芳基胺化合物的不对称氢化合成手性三级胺的方法
Peng et al. Synthesis and crystal structure of bis [(4S, 5S)-4, 5-dihydro-4, 5-diphenyl-2-(2′-oxidophenyl-χO) oxazole-χN] copper (II) and its application in the asymmetric Baeyer–Villiger reaction
CN102076634A (zh) 手性胺的合成
CN109575060B (zh) 螺环双硼催化剂的合成及其在氢化反应中的应用
Chai et al. Chiral rare-earth metal complexes with a tridentate amido-fluorenyl ligand: Syntheses, structures and catalytic performance
JP5042438B2 (ja) シン立体配置を有するβ−アミノアルコール類の製造方法
Doran et al. Neutral vs. cationic rhodium (I) complexes of bulky N-phosphino sulfinamide ligands: Coordination modes and its influence in the asymmetric hydrogenation of Z-MAC
CN102285896A (zh) 一种广谱抗菌素氯霉素的合成方法
CN101314559A (zh) 一种芳香族手性仲醇类化合物的制备方法
CN110372514A (zh) 一种催化不对称Michael加成反应的方法及其催化剂
US9340519B2 (en) Paracyclophane-based ligands, their preparation and use in catalysis
Mo et al. Asymmetric transfer hydrogenation of γ-aryl α, γ-dioxo-butyric acid esters
CN108440344A (zh) 一种高效的机械力促进的脂肪胺制备方法
CN113816865B (zh) 手性α-胺基缩醛类化合物及其衍生物的制备方法
AU2018367119B2 (en) Process for the preparation of enantiomerically and diastereomerically enriched cyclobutane amines and amides

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant